Free tool
FAERS Monitor: Rhofade
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208552 or its brand name (Rhofade, Oxymetazoline Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
910
Serious
410
45% of reports
Hospitalization
154
Death reported
26
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- application site erythema84
- drug ineffective64
- nausea55
- rosacea54
- fatigue53
- application site pain49
- erythema48
- pain47
- pruritus45
- diarrhoea44
- condition aggravated39
- headache39
- off label use37
- product dose omission issue37
- rash30
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 6 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 7 |
| 2013 | 11 |
| 2014 | 9 |
| 2015 | 11 |
| 2016 | 23 |
| 2017 | 53 |
| 2018 | 85 |
| 2019 | 79 |
| 2020 | 41 |
| 2021 | 58 |
| 2022 | 122 |
| 2023 | 132 |
| 2024 | 91 |
| 2025 | 106 |
| 2026 | 59 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,249 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| rosaceaSignal | 54 | 271.0 | 208.9 | 14,096 |
| application site erythemaSignal | 84 | 74.3 | 60.6 | 5,990 |
| application site painSignal | 49 | 51.5 | 39.2 | 2,375 |
| erythemaSignal | 48 | 5.4 | 4.1 | 169 |
| condition aggravatedSignal | 39 | 3.0 | 2.2 | 50 |
| product dose omission issueSignal | 37 | 2.9 | 2.1 | 45 |
| pruritusSignal | 45 | 2.7 | 2.0 | 48 |
| pain | 47 | 1.8 | 1.3 | 15 |
| nausea | 55 | 1.6 | 1.2 | 12 |
| rash | 30 | 1.6 | 1.1 | 6 |
| diarrhoea | 44 | 1.6 | 1.2 | 9 |
| fatigue | 53 | 1.6 | 1.2 | 11 |
| headache | 39 | 1.4 | 1.1 | 5 |
| drug ineffective | 64 | 1.1 | 0.9 | 1 |
| off label use | 37 | 1.0 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.